Taragarestrant clinical trials
Also written D-0502.
How each study uses taragarestrant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the taragarestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- D-0502
- 4
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test taragarestrant, phase 3 first.
- Nov 2026A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerPhase 3 · InventisBio Co., Ltd
Studies
Open first, then newest update. How each study uses taragarestrant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerRecruitingPhase 3InventisBio Co., LtdNCT06954961Written as D-0502
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast CancerCompletedPhase 1InventisBio Co., LtdNCT03471663Written as D-0502
- Study in Healthy Adult Female SubjectsCompletedPhase 1InventisBio Co., LtdNCT05339633Written as [14C]-D-0502
- Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female SubjectsCompletedPhase 1InventisBio Co., LtdNCT05226338Written as D-0502
- Food Effect Study of D-0502 Tablet in Healthy VolunteersCompletedPhase 1InventisBio Co., LtdNCT03810625Written as D-0502
Given beside what is tested · 1 — taragarestrant is usual care or a partner of the new treatment
Codes
What other systems call taragarestrant · ClinicalTrials.gg INT017055
- UNII (FDA) KD4HIM135VTARAGARESTRANTOne source FDA
- NCI Thesaurus C156735TaragarestrantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KD4HIM135V | TARAGARESTRANT | One source FDA |
| NCI Thesaurus | C156735 | Taragarestrant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.